Acorda Therapeutics, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 25.06% in the past one-month time frame.

The company has seen five positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Acorda Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Acorda Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

Acorda Therapeutics, Inc. Price

Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote

A better-ranked stock in the Medical sector is XOMA Corporation (XOMA Quick QuoteXOMA - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ACOR going up? Or down? Predict to see what others think: Up or Down.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>